Press Release

(April 27, 2020) - SAN DIEGO –TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced today that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA (saRNA) for COVI...

(February 11, 2020) - SAN DIEGO – TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced today the addition of two key executives to its leadership team.

Ray Kaczmarek joins TriLink as senior vice president of GMP operations. Kaczmarek, who has over 20 years of experience in pharmaceutical and biote...

(January 7, 2020) -

Advancements Expected to Accelerate Development of mRNA Therapeutics

SAN DIEGO  – TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids such as DNA and RNA, announced today that the United States Patent and Trademark Office has issued two new patents to the company. Both patents cover advancements in TriLin...

(November 20, 2019) - SAN DIEGO  – mRNA Day is being celebrated in the City of San Diego following a proclamation in honor of Maravai LifeSciences and the grand opening of its new headquarters in the City. A leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide; Maravai invested $40 million into the 105,000 square-foot headquarters located in Sorrento Valley, which featur...

(October 14, 2019) - Two New Sets of Barcode Convert Primers are Optimized for Ion Torrent* Sequencers

SAN DIEGO – TriLink BioTechnologies, a Maravai LifeSciences company and leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, introduces two new primer sets for its CleanTag® kit. The new Ion Torrent Convert barcode primer sets enable small RNA lib...

In the News

At Least 6 Companies Working on COVID Vaccines in San Diego

(10 News San Diego: June 24, 2020) - At least six companies are working on COVID-19 vaccine candidates in San Diego, all within a 1.5-mile radius of where the I-5 and I-805 split. Locally, the farthest along appears to be Inovio Pharmaceuticals, which plans to launch a Phase 2 trial next month, potentially with a simultaneous Phase 3 trial. A Phase 3 trial is the final step in vaccine testing, with thousands of participants. The company is develop...

Coronavirus: Human Trial of New Vaccine Begins in UK

(BBC News: June 24, 2020) - Volunteers have begun being immunised with a new UK coronavirus vaccine. About 300 people will have the vaccine over the coming weeks, as part of a trial led by Prof Robin Shattock and his colleagues, at Imperial College London. Tests in animals suggest the vaccine is safe and triggers an effective immune response. Experts at Oxford University have already started human trials. The trials are among many across the...

mRNA Day: TriLink, Maravai Look to RNA, Oligonucleotides, and San Diego for Growth

(Genetic Engineering & Biotechnology News: December 20, 2019) - A San Diego manufacturer of highly-modified nucleic acids and its parent company have concluded that development of RNA- and oligonucleotide-based therapeutics—as well as the region’s biopharma cluster—will both grow strongly enough in the near future to justify the companies’ recent $50-million investment in relocation and expansion within the city...

RNA Epitranscriptome: Role of the 5’ Cap

(Genetic Engineering & Biotechnology News: May 1, 2019) - Epigenetic modification of RNA, the RNA analog of the DNA epigenome, has been observed for over 40 years and is known as the epitranscriptome. Messenger RNAs (mRNAs) in particular are post-transcriptionally modified, obtaining base modifications as well as 2ʹ methylation of sugars near the 5ʹ cap. Cap modifications identify the mRNA as self rather than foreign, and modulate stability, translation, decappin...

Address Manufacturing and Look Beyond Cancer, Panel Advises Cell and Gene Therapy Companies

(Genetic Engineering & Biotechnology News: March 22, 2019) - The ability of cell and gene therapy companies to raise capital this year will hinge on their ability to address the manufacturing of their products as well as address medical needs beyond cancer, a panel of three investors and an industry executive agreed yesterday...

David Weber, Chief Commercial Officer
Maravai LifeSciences
Phone: (650) 697-3600
Email: [email protected]